Last $39.13 USD
Change Today +0.64 / 1.66%
Volume 428.4K
CPHD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Open
$38.66
Previous Close
$38.49
Day High
$39.14
Day Low
$38.36
52 Week High
03/13/14 - $55.89
52 Week Low
08/27/13 - $35.20
Market Cap
2.7B
Average Volume 10 Days
517.6K
EPS TTM
$-0.37
Shares Outstanding
70.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also provides GeneXpert Infinity System for high volume testing. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,200 Employees
Last Reported Date: 02/27/14
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $577.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $416.6K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Medical & Technology Officer, Executive...
Total Annual Compensation: $448.1K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Compensation as of Fiscal Year 2013.

cepheid inc (CPHD) Key Developments

Cepheid Updates Status of Premier Group Purchasing Organization Agreement

Cepheid announced that its group purchasing contract with Premier will end on September 30, 2014. Customers currently purchasing through the Premier GPO will be able to continue their relationship with Cepheid through other GPOs including Amerinet, Baycare, HPA, MedAssets, Novation, and ROi, in addition to the recently announced agreement with HealthTrust, or directly with the company.

Cepheid Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 09:10 AM

Cepheid Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 09:10 AM. Venue: Le Parker Meridien, New York, New York, United States.

Cepheid Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Fiscal Year Ending December 31, 2014

Cepheid reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total sales of $116.503 million against $96.012 million a year ago. Loss from operations was $5.554 million against $5.591 million a year ago. Loss before income taxes was $8.924 million against $6.308 million a year ago. Net loss was $9.843 million or $0.14 per basic and diluted share against $6,580 million or $0.10 per basic and diluted share a year ago. Non-GAAP measure of income from operations was $2.184 million against $8.821 million a year ago. Non-GAAP measure of net income was $1.195 million against $7.895 million a year ago. Non-GAAP measure of net income per share was $0.02 against $0.12 a year ago. Non-GAAP measure of income from operations was $4.249 million against $2.184 million a year ago. Non-GAAP measure of net income was $2.345 million against $1.195 million a year ago. Non-GAAP measure of net income per share was $0.03 against $0.02 a year ago. Revenue was ahead of its guidance of $113 million to $115 million driven by stronger-than-expected HBDC sales. For the six months, the company reported total sales of $223.410 million against $187.950 million a year ago. Loss from operations was $11.886 million against $5.271 million a year ago. Loss before income taxes was $17.547 million against $5.614 million a year ago. Net loss was $19.146 million or $0.27 per basic and diluted share against net loss of $6.267 million or $0.09 per basic and diluted share a year ago. Net cash used operating activities was $8.555 million against net cash provided by operating activities of $4.827 million a year ago. Capital expenditures were $25.745 million against $18.974 million a year ago. Non-GAAP measure of income from operations was $5.351 million against $10.009 million a year ago. Non-GAAP measure of net income was $1.733 million against $9.013 million a year ago. Non-GAAP measure of net income per share was $0.02 against $0.13 a year ago. For the fiscal year ending December 31, 2014, the company expects: total revenue in the range of $452 to $461 million; Net loss in a range from $0.54 to $0.51 per share; and Non-GAAP net income in the range of $0.10 to $0.13 per share. Expected non-GAAP net income excludes approximately $33 million related to stock-based compensation expense, approximately $9 million related to the amortization of debt discount and debt issuance costs, and approximately $3 million related to the amortization of acquired intangibles. The fully diluted share count for the year is expected to be approximately 70 million, except in the event it has non-GAAP net income, in which case the share count would be approximately 73 million shares. The company continues to target full year non-GAAP gross margin of approximately 52% and non-GAAP commercial gross margin of approximately 62%. For the third quarter, It expect total revenue in the range of $107 million to $110 million, reflecting sequential growth in Commercial Clinical despite the anticipated seasonal step down in Europe, partially offsetting a significant step down in HBDC. Specifically, it expects Commercial Clinical revenue in the range of $83 million to $85 million, up 16% to 19% year-over-year, and HBDC in the range of $17 million to $18 million, and expect non-Clinical to be about $7 million. The company expects non-GAAP gross margin of 52%. On the bottom line, the company expects non-GAAP EPS to range from a loss of $0.01 to a profit of $0.01 per share, and GAAP loss per share of $0.17 to $0.15. On the bottom line, it expects non-GAAP EPS to range from a loss of $0.01 to a profit of $0.01 per share, and GAAP loss per share of $0.17 to $0.15. As it moves into the fourth quarter, it expects a significant step up in revenue, which is consistent with normal seasonal trends for Commercial Clinical.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $39.13 USD +0.64

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Luminex Corp $19.12 USD +0.23
Meridian Bioscience Inc $19.70 USD -0.05
Nanosphere Inc $0.86 USD -0.0098
Quidel Corp $24.36 USD +0.53
Sequenom Inc $3.87 USD +0.09
View Industry Companies
 

Industry Analysis

CPHD

Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit www.cepheid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.